

Notes of the Formulary Management Group

Held on	Tuesday 1 st November 2016			Jubilee House, Room 1	
Members	Attended	Apologies	Absent	Designation	Abbreviation
	✓			Head of Medicines Management (Chair)	(C)
	✓			Prescribing Adviser	(PA)
		✓		GP Lead for Medicines Management	(GP)
	✓			WHT Pharmacist	(WHTP)
	✓			Primary Care Pharmacist	(PCP)
	✓			Clinical Nurse Specialist	(CNS)
			✓	Nurse Non-Medical Prescriber	(NNMP)
	✓			DWMHPT Pharmacist	(DWMHP)
		✓		DWMHPT Deputy Pharmacist	(DWMHDP)
	✓			Healthcare Governance	(HG)
			✓	Chief Pharmacist Walsall Healthcare Trust	(CPWHT)
		✓		Patient Representative	(PR)
	✓			Note Taker	
	✓			GP – Medicines Management Clinical Advisor	
	✓			Work Experience with Medicines Management Team	

	Agenda item	Actions
1	<p><u>Welcome And Apologises (Declarations of AOB)</u></p> <p>Everyone was welcomed to the November Formulary Management group meeting.</p>	
2	<p><u>Minutes Of Last Meeting</u> - Consent agenda accepted.</p> <p>The minutes from the last meeting in September were declared a true and accurate record, subject to the following amendments:</p> <ul style="list-style-type: none"> • Grammar error on page 1, misspelling of Keele. • Grammar error on page 3, misspelling of Bluteq. 	
3	<p><u>Matters Arising/Actions Sheet</u></p> <p>Degludec – Following a discussion, the committee agreed a retrospective audit of approximately 30 patients should be completed to fulfil the original requirements of the application as previously stated - A 3 month (March 2017 meeting) timeframe has been given for the submit the audit.</p> <p>Ferinject – A second invitation has been sent for the Dr and his team to attend and present the application at the December meeting – Confirmation has been received by the Dr and will be presenting the amendments at the December JMMC meeting.</p> <p>Antibiotic Formulary – PCP confirmed the draft document has three outstanding sections that need revising and amending as per the C Diff policy due to recent updates made within the hospital. After the necessary amendments, the draft document will be sent back to the microbiology team for confirmation.</p> <p>NOACs - PCP confirmed the document is still with the Dr, a second reminder has been sent for either comments/representation but still awaiting a response.</p> <p>Action – PCP to visit the Dr at the hospital to chase up a response.</p> <p>Keele Competency Training – C advised still working on this and that this may be influenced with the Regional medicines Optimisation Committees (RMOC's).</p> <p>Action – C to circulate NHSE's consultation document to the group.</p>	

Next meeting – Tuesday 6th December 2016, 1:00 – 3:30pm at Jubilee House, Room 1

Notes of the Formulary Management Group

	<p>Vortioxetine – DWMHP confirmed the prescribing initiation has been developed to record patients started on Vortioxetine within DWMHPT.</p> <p>Action – Note taker to distribute the guidance report with the group.</p> <p>Obesity Drugs – No further updates provided from C - Still awaiting confirmation.</p> <p>Action – C to chase up with Public Health for an update.</p> <p>OPEP Funding for this year – C confirmed no success so far and further updates are still required.</p> <p>Action – C to contact the Community team for an update.</p> <p>Adult ADHD Shared Care Protocol – C has picked up with Mental Health and will be leaving the action with the team as this is a commissioning issue. The GPs from June had raised comments and those have also gone back for him to also action – C confirmed this item is now complete and will be removed from the action sheet.</p> <p>Formulary Review Process</p> <ul style="list-style-type: none"> • Baby Milks Formulary – C confirmed work has not commenced as yet. • BD Autosheild Pen Needles – C agreed this item has been completed and will be removed from the action sheet. • Branded Lamotrigine/Lamictal – No further updates provided. <p>Action – PCP to follow up and will update the committee at the next meeting.</p> <p>Esyma - C still waiting for the template.</p> <p>Optimise RX message for topical Miconazole – C confirmed a message is on Optimise RX - This item is now complete and will be removed from the action sheet.</p>	
4	<p><u>Declarations of Interest</u></p> <p>A reminder that forms must be completed and returned back quarterly.</p>	
5	<p><u>Formulary Management Review Process</u></p> <p>A complex discussion took place regarding the review process for formulary which needs to follow the NICE guidance. C has asked the committee for their feedback and the item will be brought back at the next meeting in December. C also advised the committee that an email has been sent to the Dr to review the respiratory of the Formulary - Further updates to be provided at the next meeting.</p> <p>Action – C to distribute the NICE Formulary Management Review Process document to the committee.</p>	
6	<p><u>'Do not Prescribe' List</u></p> <p>C advised the committee the list has received a name change and will now be called 'Medicines of Limited Clinical Value'. The Medicines Management team are currently working on interactive drug guidelines which will be presented at the next JMMC meeting. Following on from that, any feedback/or necessary amendments from the JMMC meeting will be actioned accordingly by the team, and the draft list will be brought back to the next Formulary Management meeting in the New Year.</p> <p>Action – Note taker to send reminders to the committee to return their lists back with their comments.</p>	

Notes of the Formulary Management Group

	<p>On a separate matter, the committee advised the chair of several issues GPs are experiencing with regards to Optimise RX.</p> <p>Action - PA to investigate the optimise RX issues raised from the meeting.</p>	
7	<p><u>NICE Technology Appraisal</u></p> <p>None</p>	
8	<p><u>Non-NICE TA Drug/Devices – Full Application (JMMC Feedback)</u></p> <p>Application 138. Tapentadol – Following on from the JMMC meeting in October, a response was received back from the Pain Management Consultant and has confirmed his support with the application following a blueteq form produced for elderly and COPD patients and the committee accepted the proposal – PA is waiting for a response back by the Dr regarding the questions made at the JMMC meeting.</p> <p>Action – C to contact the Dr in regards to completing a form for Respiratory.</p> <p>Application 140. Reletrans – Following on from the previous meeting, the application has been withdrawn due to receiving no feedback for cost implications.</p> <p>Application 141. Nivolumab – The committee agreed to reject the application on this occasion and will be brought back in December for approval when a published commissioning policy is attached.</p>	
9	<p><u>Non – NICE TA Drug/Devices – Short Applications</u></p> <p>None</p>	
10	<p><u>Drug Safety Update</u></p> <ul style="list-style-type: none"> • Etorcoxib - MHRA <p>A short discussion took place regarding the above item.</p>	
11	<p><u>Horizon Scanning</u></p> <ul style="list-style-type: none"> • NICE Forward Planner – October 2016 <p>A short discussion took place regarding the above item.</p>	
12	<p><u>Appeals</u></p> <p>None</p>	
13	<p><u>Formulary Updates</u></p> <p>None</p>	
14	<p><u>Formulary Breach</u></p> <ul style="list-style-type: none"> • Victoza 1 • Victoza 2 • Victoza 3 • Lurasidone (Antipsychotic) <p>A short discussion took place regarding the above breaches. C confirmed an official invite has been sent for the consultant to attend the next upcoming meetings – No response has been received back.</p>	
15	<p><u>Recommendations to JMMC</u></p> <p>Nothing was approved at the November meeting.</p>	
16	<p><u>Any other business</u></p>	

Notes of the Formulary Management Group

	<ul style="list-style-type: none"> • KINES – New STARWAVE tool for antibiotic Rxing for children with RTI and cough • KINES – Flu Vaccines in Pregnancy • KINES – HTA report on NI inhibitors for flu • KINES – Missed opportunities in modifying use of fracture associated drugs following fragility fracture • KINES – Monthly Update <ul style="list-style-type: none"> ○ August 16 ○ September 16 • Metolazone • Mental Health ESCAs • JMMC Future <p>A brief discussion took place about the above items.</p>	
17	Finish	
These minutes are a true representation of the Group's proceeding Signed: _____ Chair _____ Date _____		

These minutes will be redacted to remove names/initials before publication

Future Meeting Dates

Date	Month	Year	Venue	Date	Month	Year	Venue
				6 th	December	2016	Room1

Date	Month	Year	Venue	Date	Month	Year	Venue
3 rd	January	2017	Room1	4 th	July	2017	Room1
7 th	February	2017	Room1	1 st	August	2017	Room1
7 th	March	2017	Room1	5 th	September	2017	Room1
4 th	April	2017	Room1	3 rd	October	2017	Room1
2 nd	May	2017	Room1	7 th	November	2017	Room1
6 th	June	2017	Room1	5 th	December	2017	Room1

Date	Month	Year	Venue	Date	Month	Year	Venue
2 nd	January	2018	Room1	3 rd	July	2018	Room1
6 th	February	2018	Room1	7 th	August	2018	Room1
6 th	March	2018	Room1	4 th	September	2018	Room1
3 rd	April	2018	Room1	2 nd	October	2018	Room1
1 st	May	2018	Room1	6 th	November	2018	Room1
5 th	June	2018	Room1	4 th	December	2018	Room1

Next meeting – Tuesday 6th December 2016, 1:00 – 3:30pm at Jubilee House, Room 1